Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/LSD/Opioid Use Disorder (OUD)

LSD for Opioid Use Disorder (OUD)

9 papers and 0 clinical trials exploring lsd as a treatment for opioid use disorder (oud).

Compoundclassic psychedelic

LSD

LSD is a classic psychedelic ergoline with high potency at microgram doses and an 8-12 hour duration of action, mediated primarily via 5-HT2A receptor agonism. Modern Phase IIb data in generalised anxiety disorder and FDA Breakthrough Therapy Designation for MM120 have reignited clinical development.

Full LSD profile
IndicationAn estimated 2 million people in the United States have OUD.

Opioid Use Disorder (OUD)

Opioid Use Disorder (OUD) is a prevalent and serious public health issue that is increasingly being targeted for treatment with psychedelics, particularly ibogaine. Recent studies suggest that these compounds may alleviate withdrawal symptoms and reduce cravings, presenting a potential shift in therapeutic approaches to OUD.

Full Opioid Use Disorder (OUD) profile

Academic Research

9 papers
Open Accessindividual

LSD use in the United States: Examining user demographics and their evolution from 2015-2019

Analysing NSDUH data from 2015–2019, the authors found a 47% increase in past‑year LSD use (0.59% to 0.87%) without a proportional rise in hallucinogen use disorder. Use was linked to greater access and lower perceived risk plus specific sociodemographic and behavioural correlates (e.g. Asian race, low income, fewer children, history of selling drugs, past‑year suicide attempt in adults) and rose among pregnant, 26–34‑year‑old, married respondents and lifetime methamphetamine users, suggesting growing societal acceptance though LSD remains uncommon and not a major driver of public‑health harm.

Published
December 26, 2022
Journal
MedRvix
Authors
Weleff, J., Anand, A., Dewey, E. N., Barnett, B. S.
Open Accessindividual

Hopelessness, Suicidality, and Co-Occurring Substance Use among Adolescent Hallucinogen Users-A National Survey Study

Analysing nationally representative YRBSS data from 2001–2019 (125,550 students), 8.4% of adolescents reported lifetime hallucinogen use, declining from 13.3% to 7.0% over the period. Hallucinogen users had significantly higher odds of feeling sad or hopeless, suicidal ideation and planning, and markedly greater co‑occurring use of alcohol, tobacco, cannabis and other illicit drugs.

Published
December 5, 2022
Journal
Children
Authors
Desai, S., Jain, V., Xavier, S., Du, W.
Open Accessindividual

Associations between classic psychedelics and nicotine dependence in a nationally representative sample

In a nationally representative sample of 214,505 US adults, lifetime use of psilocybin, peyote and mescaline was associated with modestly lower odds of current nicotine dependence, whereas lifetime LSD use was associated with higher odds; experimental studies are needed to establish causality and assess therapeutic potential for smoking cessation.

Published
June 22, 2022
Journal
Scientific Reports
Authors
Jones, G. M., Lipson, J., Nock, M. K.
Open Accessindividual

Associations between classic psychedelics and opioid use disorder in a nationally-representative U.S. adult sample

Using data from the National Survey on Drug Use and Health (2015–2019; N = 214,505), lifetime psilocybin use was associated with significantly lower odds of opioid use disorder (adjusted OR 0.70, 95% CI 0.60–0.83), while other classic psychedelics showed no such association, and psilocybin use was linked to reduced odds for seven of 11 DSM‑IV OUD criteria. These observational findings suggest psilocybin merits further investigation in longitudinal and clinical trials to assess causality.

Published
April 7, 2022
Journal
Scientific Reports
Authors
Jones, G. M., Ricard, J. A., Lipson, J., Nock, M. K.
Open Accessindividual

Use of psilocybin (“mushrooms”) among US adults: 2015-2018

Pooled 2015–2018 NSDUH data from 168,650 US adults show 9.68% reported lifetime psilocybin use, with higher prevalence among bisexual-identifying individuals and substantial overlap with LSD, methamphetamine and heroin users. These findings can inform harm-reduction efforts and behavioural‑health messaging.

Published
May 11, 2021
Journal
Journal of Psychedelic Studies
Authors
Yockey, R. A., King, K. A.
Paywallmeta

Do Hallucinogens Have a Role in the Treatment of Addictions? A Review of the Current Literature

This paper (2021) reviews the current literature regarding LSD, psilocybin, ketamine, ibogaine, and ayahuasca as potential treatments for addiction. The authors conclude that the available evidence is promising, but that more robust research is needed.

Published
March 31, 2021
Journal
SN Comprehensive Clinical Medicine
Authors
Nigam, K. B., Pandurangi, A. K.

Clinical Trials

0 trials

No clinical trials have been tagged with both LSD and Opioid Use Disorder (OUD) yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all LSD papers Search all Opioid Use Disorder (OUD) trials Full LSD profile Full Opioid Use Disorder (OUD) profile